Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Clinical trial NCT07720180 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07720180
- Sponsor
- Medical University of South Carolina
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-12-01
- Primary completion
- 2031-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.